Sera Prognostics宣布早产风险评估与临床干预相结合的结果，以改善新生儿OutcoME研究已接受在同行评审杂志上发表

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year

SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal.

The PRIME study's abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.